A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2014
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 02 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 24 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 14 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.